Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Up 74.6% in July

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 1,448,757 shares, an increase of 74.6% from the June 30th total of 829,522 shares. Approximately 1.9% of the shares of the stock are short sold. Based on an average daily volume of 1,113,100 shares, the days-to-cover ratio is presently 1.3 days.

Nautilus Biotechnology Stock Performance

Shares of Nautilus Biotechnology stock traded down $0.01 on Thursday, hitting $1.02. The stock had a trading volume of 452,153 shares, compared to its average volume of 480,382. The stock has a 50 day moving average of $2.08 and a 200 day moving average of $2.43. The firm has a market capitalization of $130.26 million, a P/E ratio of -2.28 and a beta of 0.80. Nautilus Biotechnology has a twelve month low of $0.62 and a twelve month high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its earnings results on Tuesday, July 28th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.10 million.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $4.00.

Insider Buying and Selling at Nautilus Biotechnology

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the sale, the insider owned 971,885 shares in the company, valued at approximately $2,283,929.75. This trade represents a 83.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 41.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC lifted its holdings in Nautilus Biotechnology by 19.6% during the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after buying an additional 3,849 shares during the period. Bridgeway Capital Management LLC lifted its stake in shares of Nautilus Biotechnology by 4.0% in the fourth quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock worth $254,000 after acquiring an additional 5,000 shares during the period. Renaissance Technologies LLC boosted its holdings in Nautilus Biotechnology by 2.2% in the first quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock valued at $1,031,000 after acquiring an additional 5,800 shares during the last quarter. Geode Capital Management LLC increased its position in Nautilus Biotechnology by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock valued at $1,094,000 after purchasing an additional 7,307 shares during the period. Finally, CTC Alternative Strategies Ltd. acquired a new stake in Nautilus Biotechnology during the 1st quarter valued at approximately $48,000. 50.71% of the stock is owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.